Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

605 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ovarian Suppression: Early Menopause and Late Effects.
Molinelli C, Jacobs F, Nader-Marta G, Borea R, Scavone G, Ottonello S, Fregatti P, Villarreal-Garza C, Bajpai J, Kim HJ, Puglisi S, de Azambuja E, Lambertini M. Molinelli C, et al. Among authors: jacobs f. Curr Treat Options Oncol. 2024 Apr;25(4):523-542. doi: 10.1007/s11864-024-01190-8. Epub 2024 Mar 13. Curr Treat Options Oncol. 2024. PMID: 38478329 Free PMC article. Review.
HER2-Low Breast Cancer: Where Are We?
Molinelli C, Jacobs F, Marchiò C, Pitto F, Cosso M, Spinaci S, de Azambuja E, Schettini F, Agostinetto E, Lambertini M. Molinelli C, et al. Among authors: jacobs f. Breast Care (Basel). 2022 Dec;17(6):533-545. doi: 10.1159/000527391. Epub 2022 Oct 6. Breast Care (Basel). 2022. PMID: 36590146 Free PMC article. Review.
Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis.
Molinelli C, Jacobs F, Agostinetto E, Nader-Marta G, Ceppi M, Bruzzone M, Blondeaux E, Schettini F, Prat A, Viale G, Del Mastro L, Lambertini M, de Azambuja E. Molinelli C, et al. Among authors: jacobs f. ESMO Open. 2023 Aug;8(4):101592. doi: 10.1016/j.esmoop.2023.101592. Epub 2023 Jul 4. ESMO Open. 2023. PMID: 37413762 Free PMC article.
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab.
Debien V, Marta GN, Agostinetto E, Sirico M, Jacobs F, Molinelli C, Moreau M, Paesmans M, De Giorgi U, Santoro A, Taylor D, Duhoux FP, Botticelli A, Barchiesi G, Speranza I, Lambertini M, Wildiers H, Azambuja E, Piccart M. Debien V, et al. Among authors: jacobs f. Crit Rev Oncol Hematol. 2023 Oct;190:104089. doi: 10.1016/j.critrevonc.2023.104089. Epub 2023 Aug 9. Crit Rev Oncol Hematol. 2023. PMID: 37562696 Review.
Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysis.
Jacobs F, Molinelli C, Martins-Branco D, Marta GN, Salmon M, Ameye L, Piccart M, Lambertini M, Agostinetto E, de Azambuja E. Jacobs F, et al. Eur J Cancer. 2024 Jan;197:113478. doi: 10.1016/j.ejca.2023.113478. Epub 2023 Dec 12. Eur J Cancer. 2024. PMID: 38103328
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial.
Debien V, Agostinetto E, Bruzzone M, Ceppi M, Martins-Branco D, Molinelli C, Jacobs F, Nader-Marta G, Lambertini M, de Azambuja E. Debien V, et al. Among authors: jacobs f. Clin Breast Cancer. 2024 Feb 21:S1526-8209(24)00050-8. doi: 10.1016/j.clbc.2024.02.012. Online ahead of print. Clin Breast Cancer. 2024. PMID: 38514306
HR+/HER2- de novo metastatic breast cancer: a true peculiar entity?
Torrisi R, Jacobs F, Miggiano C, De Sanctis R, Santoro A. Torrisi R, et al. Among authors: jacobs f. Drugs Context. 2023 Mar 6;12:2022-12-2. doi: 10.7573/dic.2022-12-2. eCollection 2023. Drugs Context. 2023. PMID: 36926051 Free PMC article. Review.
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.
Gerosa R, De Sanctis R, Jacobs F, Benvenuti C, Gaudio M, Saltalamacchia G, Torrisi R, Masci G, Miggiano C, Agustoni F, Pedrazzoli P, Santoro A, Zambelli A. Gerosa R, et al. Among authors: jacobs f. Crit Rev Oncol Hematol. 2024 Apr;196:104324. doi: 10.1016/j.critrevonc.2024.104324. Epub 2024 Mar 8. Crit Rev Oncol Hematol. 2024. PMID: 38462150 Free article. Review.
Ribociclib-Induced Cutaneous Adverse Events in Metastatic HR+/HER2- Breast Cancer: Incidence, Multidisciplinary Management, and Prognostic Implication.
Borroni RG, Bartolini M, Gaudio M, Jacobs F, Benvenuti C, Gerosa R, Tiberio P, Manara SAAM, Solferino A, Santoro A, De Sanctis R. Borroni RG, et al. Among authors: jacobs f. Oncologist. 2024 Jan 18:oyae004. doi: 10.1093/oncolo/oyae004. Online ahead of print. Oncologist. 2024. PMID: 38242689 Free article.
605 results